AAM S&P Developed Markets High Dividend Value ETF
DMDV
DMDV was delisted on the 17th of October, 2024.
3 hedge funds and large institutions have $530K invested in AAM S&P Developed Markets High Dividend Value ETF in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 1 closing their positions.
16% less capital invested
Capital invested by funds: $627K → $530K (-$97.2K)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LNWWM
Laird Norton Wetherby Wealth Management
San Francisco,
California
|
-$195K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.71K |
| 3 |
Jane Street
New York
|
-$935 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$19 |
DMDV Hedge Fund Activity: Q4 2022 in Review
3 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in AAM S&P Developed Markets High Dividend Value ETF (DMDV) for Q4 2022, worth a combined $530K — down 16% from $627K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DMDV and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest seller was Laird Norton Wetherby Wealth Management, cutting an estimated $195K.
- 3 institutional investors held AAM S&P Developed Markets High Dividend Value ETF (DMDV) as of Q4 2022, down from 4 in Q3 2022.
- Funds reported $530K of AAM S&P Developed Markets High Dividend Value ETF stock for Q4 2022, down 16% quarter-over-quarter.
- 0 funds opened new AAM S&P Developed Markets High Dividend Value ETF positions in Q4 2022 and 1 closed out, a net change of -1 holder.
- The largest AAM S&P Developed Markets High Dividend Value ETF seller in Q4 2022 was Laird Norton Wetherby Wealth Management, an estimated $195K sold.
Based on aggregated 13F filings for Q4 2022.